A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.
Aurinia hopes to light up with Aurora data, while Principia's BTK inhibitor PRN1008 is put to the test.
A phase III win for Roche’s satralizumab has added to Alexion’s Soliris woes.
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
The extensively overhauled Tulip-2 study of anifrolumab in lupus is an unexpected success.
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Chemocentryx and Sanofi are looking to target the complement pathway in ANCA-associated vasculitis and cold agglutinin disease respectively, with phase III data due in…
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
Pexa-Vec fails earlier than expected, dealing exuberant South Korean biotech investors and the oncolytic virus field another blow.